SCHEMBL4050818

SCHEMBL4050818

COc1cccc(CCc2nc3ncc(-c4ccco4)cc3[nH]2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS1 P29475 5/20 0.55
NOS2 P35228 5/20 0.55
NOS3 P29474 4/20 0.55
SMN1; SMN2 Q16637 2/20 0.47
LMNA P02545 1/20 0.47
HTT P42858 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47
CYP2C9 P11712 1/20 0.45
ADORA2A P29274 6/20 0.42
ADORA1 P30542 6/20 0.42
ALDH1A1 P00352 3/20 0.42
HDAC1 Q13547 1/20 0.41
ADORA3 P0DMS8 4/20 0.41
ADORA2B P29275 4/20 0.41
IKBKE Q14164 1/20 0.40
TBK1 Q9UHD2 1/20 0.40
KDM4E B2RXH2 1/20 0.40
NPC1 O15118 1/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4058754 0.91 NOS3 (0.48) NOS1NOS2NOS3SMN1; SMN2LMNA
SCHEMBL4055769 0.90 NOS1 (0.54) NOS1NOS2NOS3SMN1; SMN2LMNA
SCHEMBL4062481 0.86 NOS3 (0.48) NOS1NOS2NOS3SMN1; SMN2LMNA
SCHEMBL4060650 0.85 NOS3 (0.49) NOS1NOS2NOS3SMN1; SMN2LMNA
SCHEMBL4058842 0.85 MEN1 (0.41) NOS1NOS2NOS3SMN1; SMN2LMNA
SCHEMBL4054567 0.84 NOS1 (0.72) NOS1NOS2NOS3SMN1; SMN2LMNA
SCHEMBL4055085 0.84 NOS1 (0.48) NOS1NOS2NOS3SMN1; SMN2CYP2C9
SCHEMBL13608640 0.84 HDAC1 (0.43) SMN1; SMN2HTTADORA2AADORA1ALDH1A1
SCHEMBL4061708 0.83 NOS1 (0.46) NOS1NOS2NOS3SMN1; SMN2LMNA
SCHEMBL4057348 0.82 NOS3 (0.48) NOS1NOS2NOS3SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B NOS1 879/4885NOS2 1019/4885NOS3 907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.